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Abstract Prader–Willi syndrome (PWS) is characterized
by a switch from failure to thrive to excessive weight gain
and hyperphagia in early childhood. Hyperghrelinemia may
be involved in the underlying mechanisms of the switch. The
purpose of this study is to evaluate acylated ghrelin (AG) and
unacylated ghrelin (UAG) levels in PWS and investigate
their associations with hyperphagia. This is a cross-sectional
clinical study conducted in three PWS expert centers in the
Netherlands and France. Levels of AG and UAG and the AG/
UAG ratio were determined in 138 patients with PWS
(0.2–29.4 years) and compared with 50 age-matched obese
subjects (4.3–16.9 years) and 39 healthy controls
(0.8–28.6 years). AEBSF was used to inhibit deacylation of
AG. As a group, PWS patients had higher AG but similar
UAG levels as healthy controls (AG 129.1 vs 82.4 pg/ml,
p = 0.016; UAG 135.3 vs 157.3 pg/ml, resp.), resulting in a
significantly higher AG/UAG ratio (1.00 vs 0.61, p = 0.001,
resp.). Obese subjects had significantly lower AG and UAG
levels than PWS and controls (40.3 and 35.3 pg/ml, resp.),
but also a high AG/UAG ratio (1.16). The reason for the
higher AG/UAG ratio in PWS and obese was, however,
completely different, as PWS had a high AG and obese a very
low UAG. PWS patients without weight gain or hyperphagia
had a similar AG/UAG ratio as age-matched controls, in
contrast to those with weight gain and/or hyperphagia who
had an elevated AG/UAG ratio. The switch to excessive
weight gain in PWS seems to coincide with an increase in the
AG/UAG ratio, even prior to the start of hyperphagia.
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Introduction
Prader–Willi syndrome (PWS) is a neurogenetic disorder
caused by the lack of expression of the paternally derived
genes on chromosome 15 at locus q11–q13 [1]. Clinical
findings change when children become older: infancy is
characterized by poor feeding, failure to thrive, and mus-
cular hypotonia, while hyperphagia with impaired satiety,
obesity, short stature, psychomotor delay, and behavioral
problems are prominent during childhood and adulthood
[2, 3]. The mechanism behind the switch from failure to
thrive to excessive weight gain and hyperphagia in early
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childhood is not yet known, but hyperghrelinemia might be
involved [4, 5].
Most children with PWS nowadays receive growth
hormone (GH) treatment, which counteracts the clinical
course of obesity and improves the metabolic profile,
leading to better lipid levels, higher adiponectin levels, and
lower systolic blood pressure [6, 7]. However, GH treat-
ment does not solve the problem of hyperphagia.
The appetite-stimulating hormone ghrelin has an acy-
lated and an unacylated form in circulation [8–10]. Acy-
lated ghrelin (AG) is known to be diabetogenic and has
many actions such as stimulating appetite and inducing a
positive energy balance, which can lead to weight gain
[11–14]. Intravenous AG administration in healthy volun-
teers increased food intake and appetite [15], suggesting
that the hyperphagia in PWS might be associated with in-
creased ghrelin levels. For a long time, unacylated ghrelin
(UAG) was considered to be an inactive degradation pro-
duct of AG. Currently, there is increasing evidence that
UAG has also distinct actions [16]. It is reported that UAG
has protective effects on beta cells, endothelial progenitor
cells, and muscle cells, and UAG seems to improve gly-
cemic control [14]. In addition, UAG acts as a functional
inhibitor of AG and it was reported to suppress ghrelin
levels in humans [16, 17]. This suggests a crucial role for
the ratio of AG and UAG levels (AG/UAG ratio) in
maintaining weight balance.
Ghrelin can be determined in blood samples, but AG is
unstable and is rapidly deacylated to UAG through the
action of esterases [18, 19]. Thus, reliable ghrelin deter-
mination needs the immediate addition of an esterase in-
hibitor at the time of blood collection. In patients with
PWS, hyperghrelinemia has been reported, but in these
studies, samples were not treated in this way [4, 5, 20–23].
We formulated three hypotheses. Children and young
adults with PWS have (1) higher AG levels and lower
UAG levels than healthy and obese controls; (2) in-
creasing AG and decreasing UAG levels with the rise of
the nutritional phases, resulting in increased AG/UAG
ratios in the higher nutritional phases; and (3) a higher
AG/UAG ratio in the presence of weight gain and/or
hyperphagia and a normal AG/UAG ratio in the absence
of weight gain and/or hyperphagia, compared with age-
matched healthy controls.
Therefore, a cross-sectional study was conducted in
which we measured the plasma levels of AG and UAG in
children and young adults with PWS and compared these
levels with those of obese and healthy controls. AEBSF, an
inhibitor of deacylation of AG, was immediately added to all
blood samples. In patients with PWS, we investigated the
associations between AG and UAG ghrelin levels and the
following factors: age, BMI, genotype, eating behavior and
food intake. In addition, we investigated whether the switch
from failure to thrive to excessive weight gain and hyper-
phagia is associated with a change in the AG/UAG ratio.
Subjects and methods
Subjects
The study group consisted of 138 children and young
adults with PWS, either participating in the Dutch PWS
studies coordinated by the Dutch Growth Research Foun-
dation, or followed at the PWS reference center in Tou-
louse or Children’s Hospital in Lyon. PWS was genetically
confirmed in all patients. One hundred and seven patients
(77.5 %) were treated with GH, and the others had not yet
started with GH or had reached final height without pos-
sibilities to continue GH treatment or the parents refused
the GH treatment. Three patients with PWS had diabetes
mellitus type 2 (DM2) and all were treated with metformin.
As their ghrelin levels were similar as in the total PWS
group, we did not exclude them from analyses. None of the
healthy or obese controls had DM2.
Plasma ghrelin levels of subjects with PWS (PWS) were
compared with 50 obese subjects (obese) and 39 healthy
controls (controls). Obese and controls suffering from any
systemic illness, growth disorder, syndrome, or having
dysmorphic features were excluded. Obese children had a
BMI[?2 SDS and were regularly seen in the outpatient
department of the pediatric endocrinology unit in Toulouse.
Healthy controls were children and young adults with a
normal BMI, who underwent a minor surgical procedure at
Erasmus Medical Center in Rotterdam. Normal BMI was
defined as a BMI between -2 SDS and ?2 SDS [24].
Standing height was measured with a calibrated
Harpenden stadiometer or, when appropriate, supine length
with a Harpenden infantometer (Holtain Ltd). Weight was
determined on a calibrated scale (Servo Balance KA-20-
150S; Servo Berkel Prior) and BMI was calculated. Height,
weight and BMI were expressed as SDS, adjusted for age
and sex. The Dutch reference data were used for the Dutch
children and young adults [24, 25], and the French refer-
ence data for height and weight and the Cole BMI refer-
ence data were used for the French patients [26, 27]. All
SDS values were calculated with Growth Analyser (version
4.0; www.growthanalyser.org).
The Medical Ethics Committees of the 3 participating
centers approved the study. Written informed consent was
obtained from parents of PWS. For obese and controls,
written informed consent was obtained from themselves
and, if they were younger than 18 years, also from their
parents or custodians.
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Eating behavior
The nutritional phases according to Miller were used to
score the eating behavior of the subjects with PWS [3]: 1a
Hypotonia with difficulty feeding, 1b No difficulty feeding
and growing appropriately on growth curve, 2a Weight
increasing without an increase in appetite or excessive
calories, 2b Weight increasing with an increase in ap-
petite or excessive calories, 3 Hyperphagia, feels rarely
full, and 4 Appetite no longer insatiable. For each subject
with PWS, the nutritional phase was assessed by the mul-
tidisciplinary teams or independently by two observers who
knew them very well (physician and nurse) [3]. In case of
disagreement, the case was discussed until consensus was
reached. Subjects with PWS without weight gain or hy-
perphagia, defined as being in nutritional phase 1a or 1b,
and subjects with weight gain and/or hyperphagia, defined
as being in phases 2a, 2b, and 3, were compared with age-
matched controls.
Collection of blood and plasma preparation
In children[2 years, blood samples were collected in the
morning after a 12-h overnight fast. Infants\2 years were
fasted for at least 5-h. To stabilize the plasma ghrelin
levels, blood samples were collected in EDTA tubes, and
4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride
(AEBSF, Sigma-Aldrich Chemicals) was added to a con-
centration of 2 mg/ml at the time of collection. Blood was
centrifuged at 4 C to prepare plasma, which was quickly
frozen on dry ice. Samples were stored at -80 C and
assayed within 3 months following collection.
Assays
Plasma AG and UAG levels were assessed in duplicate (10-50
lL per well) in one laboratory using two-step double-antibody
sandwich EIAs, obtained from SPIBio (Bertin Pharma,
France; A05306 and A05319, resp.). Assays were performed
according to manufacturer’s instructions. In summary, stan-
dards, quality controls, and samples were incubated in the
plate for 2 h at room temperature without tracer. After a 39
wash, tracer antibody was added and incubated for 2 h at room
temperature. Following a 59 wash, Ellman’s reagent was
added and incubated for approximately 45 min until satis-
factory color development. Finally, the absorbance was
measured at 405 nm using a VictorX4 plate reader (Perk-
inElmer, Groningen, Netherlands).
Data were analyzed using Graphpad Prism 5 (La Jolla,
California). A sigmoidal third-order (cubic) polynomial
fitting was used to determine concentrations from the
calibration curves. This resulted in r2 values[0.99 in the
majority of the assays. Intra-assay coefficient of variations
(CVs) for AG and UAG were 8.2 and 11.4 %, and in-
terassay CVs for AG and UAG were 3.9 and 11.0 %. CVs
were determined over 10 and 9 assays for AG and UAG,
resp. Samples had inter-duplicate CV of \20 % for both
AG and UAG. The AG/UAG ratio was computed as AG
divided by UAG.
In Rotterdam, insulin levels were assessed using the
Immulite 2000 assay (Siemens Healthcare Diagnostics).
Interassay CV was 4.4 %. Serum glucose levels were de-
termined using the Hitachi 917 (Hitachi Device Develop-
ment Center), detecting glucose levels between 0 and
42 mmol/l. Serum IGF-I levels were assessed using the
IDS-iSYS (Immunodiagnostic Systems). The intra-assay
CV was \6.0 % and the interassay CV was \2.1 %. In
France, insulin and glucose were enzymatically assessed on
the Beckman AU 2700 (Beckman Coulter Inc) and serum
IGF-I levels were measured using IRMA assay from Im-
munotech. The intra-assay CV was \6.3 % and the in-
terassay CV was \8.8 %. For Rotterdam and France,
homeostasis model assessment of insulin resistance
(HOMA-IR) was performed using the model HOMA-
IR = [fasting insulin (mU/l) 9 fasting glucose (mmol/l)]/
22.5 [28].
Statistics
Statistical analysis was performed by the Statistical Pack-
age for Social Sciences (version 20.0; SPSS, Chicago, IL).
Data are expressed as median [interquartile range (IQR)].
Differences between the groups were calculated using
Kruskal–Wallis tests when comparing three groups and
Mann–Whitney U tests when comparing two groups. Pa-
tients with PWS in each nutritional phase were compared
with age-matched healthy controls. Obese PWS, defined as
BMI[?2 SDS, were compared with obese controls. AG
and UAG levels and AG/UAG ratios were log-transformed
(natural logarithm), as they were not normally distributed.
In PWS patients, we cross-sectionally assessed linear cor-
relations between ghrelin levels and other parameters using
Spearman’s rho correlation coefficient (q). As levels of AG
and UAG decreased with age, linear regression analysis
was used to compare groups with adjustment for age. The
AG/UAG ratio was not adjusted for age, as it remained
stable across ages. Linear regression analysis was used to
analyze correlations with adjustment for parameters such
as age and gender. Regression coefficients are presented as
percentages for better interpretation of the results. A
positive value indicates that the dependent variable is in-
creased by that % for every unit increase of the indepen-
dent variable. Differences were considered significant if the
p value was\0.05.
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Results
Clinical characteristics
Median [IQR] age of PWS was 9.9 [4.1–14.9] years
(Table 1). There was no significant difference in age be-
tween the 138 PWS (61 boys), 39 controls (13 boys), and
50 obese (16 boys). Height, weight and BMI were sig-
nificantly different between the three groups and highest in
obese (p\ 0.001). Fasting insulin and HOMA-IR were
higher in obese (p\ 0.001 and p = 0.001, resp.), while
fasting glucose and IGF-I SDS were highest in PWS
(p = 0.043 and p\ 0.001, resp.).
PWS was genetically confirmed by an abnormal
methylation test in all subjects with PWS. In 131 (94.9 %)
subjects, the genetic subtype was known; seventy (50.7 %)
had a deletion, 55 (39.9 %) a uniparental maternal disomy
(mUPD), and 6 (4.3 %) an imprinting center mutation. One
hundred and seven PWS used GH (77.5 %) with a median
dose of 0.85 mg/m2/day [0.61–1.0] (&0.028 mg/kg/day).
Median age at start of GH treatment was 1.9 [1.1–4.3]
years and median duration of GH treatment was 7.0
[3.2–9.1] years.
Ghrelin levels in the three groups
Median [IQR] AG was significantly higher in the PWS
group (129.1 [67.1–227.9] pg/ml) than in controls (82.4
[56.3–130.4] pg/ml, p = 0.016). UAG was similar in PWS
and controls. As a result, the AG/UAG ratio was sig-
nificantly higher in PWS than in controls (p = 0.001)
(Table 2; Fig. 1).
In PWS, both AG and UAG levels were significantly
higher than in obese (both p\ 0.001), as obese had the
lowest AG and UAG levels of the three groups. Both PWS
and obese had a significantly higher AG/UAG ratio than
controls. The reason for the higher AG/UAG ratios in PWS
and obese was, however, different. PWS had high AG
levels, resulting in this higher AG/UAG ratio, while obese
had low AG levels with even lower UAG levels.
In all three groups, both AG and UAG levels decreased
with age, but the AG/UAG ratio remained stable.
Ghrelin in nutritional phases in PWS
Of the 138 PWS who were classified according to the
nutritional phases of Miller [3], 13 patients were in phase
1a, 37 in phase 1b, 12 in phase 2a, 44 in phase 2b, 31 in
phase 3, and 1 in phase 4 (Table 3). The median age of the
children with PWS in nutritional phase 1b was 8.9 years,
while the median age of the children in nutritional phase 2a
was 3.5 years younger, namely 5.3 years. It shows that the
rise of the nutritional phases was not in line with an older
age. A considerable number of older subjects with PWS
were still in nutritional phase 1b. Parallel with the rise of
the nutritional phases, children with PWS in the higher
nutritional phases had a higher BMI, ranging from -2.0
SDS in phase 1a to ?3.2 SDS in phase 4.
Ghrelin levels and the switch in eating behavior
in PWS
Both AG and UAG levels of PWS patients decreased with
the rise of the nutritional phases (Table 3, supplemental
figure). Between phase 1b and phase 2a, AG levels de-
creased from 161.0 to 117.2 pg/ml and UAG levels de-
creased from 252.0 to 125.5 pg/ml, but probably due to the
low number in phase 2a, this did not reach statistical sig-
nificance. Subsequently, the AG and UAG levels of the
patients in nutritional phase 2a, 2b, and 3 remained con-
sistently low. The AG/UAG ratio showed a marked in-
crease between phase 1b and phase 2a and then remained
consistently high in phases 2a, 2b, and 3. This shows that
the elevated AG/UAG ratio is already present in phase 2a,
prior to phases 2b and 3 in which the hyperphagia occurs.
Differences in ghrelin levels between nutritional phase
1b and 2a did not reach statistical significance. As ghrelin
Table 1 Baseline
characteristics of 138 PWS,
39 healthy controls and 50
obese subjects
PWS n = 138 Controls n = 39 Obese n = 50
Median (IQR) Median (IQR) Median (IQR) p*
Age (years) 9.9 (4.1 to 14.9) 7.3 (3.6 to 13.6) 9.8 (7.9 to 13.0) 0.350
Weight for age (SDS) 0.8 (-0.6 to 2.4) -0.2 (-0.8 to 0.5) 5.9 (4.5 to 7.0) <0.001
Height for age (SDS) -0.3 (-1.3 to 0.6) -0.1 (-0.8 to 0.4) 1.3 (0.8 to 2.5) <0.001
BMI for age (SDS) 1.0 (-0.2 to 2.1) -0.2 (-0.8 to 0.8) 2.8 (2.6 to 3.1) <0.001
Fasting glycemia (mmol/l) 4.5 (4.0 to 5.0) 4.3 (3.9 to 4.7) 0.043
Fasting insulin (pmol/l) 62.5 (34.7 to 90.3) 100.7 (76.4 to 123.3) <0.001
HOMA-IR 1.8 (1.0 to 2.8) 2.6 (1.9 to 3.6) 0.001
IGF-I (SDS) 0.7 (0.7 to 1.7) -0.5 (-1.2 to 0.3) <0.001
Bold values are statistically significant (p\ 0.05)
* p value between the three groups; 138 PWS, 39 healthy controls and 50 obese controls
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levels were similar in phase 2a, 2b, and 3, these nutritional
phases were combined. Eighty-seven PWS had weight gain
and/or hyperphagia (nutritional phase 2a, 2b, and 3). These
87 PWS had significantly higher AG/UAG ratios than the
50 PWS who did not have weight gain or hyperphagia
(nutritional phases 1a and 1b) (p = 0.009) (Fig. 2). This
shows that the switch to weight gain and/or hyperphagia
seems to occur simultaneously with the increase in the AG/
UAG ratio.
Ghrelin levels in PWS and age-matched controls
While the AG/UAG ratio was similar in PWS in phase 1a
and 1b as in age-matched controls, the AG/UAG ratio was
significantly higher in nutritional phase 2b and 3 than in
age-matched controls. The AG/UAG ratio in PWS in phase
2a was similar as in phase 2b and 3, but was not sig-
nificantly higher than age-matched controls, probably due
to the low number in phase 2a (Table 3; Fig. 2).
Non-obese PWS vs healthy controls and obese PWS
vs obese controls
In an additional analysis, we compared 100 non-obese PWS
with a median [IQR] BMI of?0.4 [-0.9 to 1.2] SDS with 39
healthy controls (BMI -0.2 SDS [-0.8 to 0.8]). The results
were comparable with the data of the total group (Table 4).
The AG levels were significantly higher in non-obese PWS
than in healthy controls (median 140.1 vs 82.4 pg/ml,
p = 0.005), while the UAG levels were similar (median
150.7 vs 157.3 pg/ml, NS), resulting in a significantly higher
AG/UAG ratio in non-obese PWS (0.89 vs 0.61, p = 0.003).
We also compared the ghrelin levels of 38 obese PWS
with a median [IQR] BMI of ?2.7 SDS [2.4–3.2] with 50
obese controls (BMI ?2.8 SDS [2.6–3.1]). Both AG and
UAG levels were significantly higher in obese PWS than in
obese controls (median 100.1 and 94.9 pg/ml vs 40.3 and
35.8 pg/ml resp., both p\ 0.001, even after adjustment for
age), but the AG/UAG ratio was similar in both groups
(1.08 vs 1.16, p = 0.730).
Associations between ghrelin levels and clinical
characteristics and HOMA-IR in PWS
There were no significant differences in AG and UAG levels
and AG/UAG ratio between boys and girls, or between pa-
tients with a deletion and an mUPD. AG was inversely as-
sociated with age (p = 0.012), weight SDS (p = 0.004) and
BMI SDS (p = 0.001), and similar inverse associations
were found between UAG and age, weight SDS and BMI
SDS (all p\ 0.001). Since both AG and UAG decreased
with age, the association analyses were adjusted for the
variables age and gender. Higher BMI SDS was associated
with lower AG and UAG levels, also after correction for age
and gender (not shown). If the BMI SDS would increase with
1 SDS, the AG level would decrease by 22.8 % and the UAG
by 21.0 %. The association between BMI SDS and AG/
UAG ratio was not significant.
AG and UAG were both inversely associated with
fasting insulin (p = 0.023 and p\ 0.001, resp.), and UAG
with HOMA-IR (p = 0.004). After adjustment for the
variables age and gender, these associations remained
significant (p = 0.048 and p = 0.031 for insulin,
p = 0.050 for HOMA-IR). The AG/UAG ratio was not
associated with insulin or HOMA-IR.
Associations between ghrelin and IGF-I levels
in PWS
IGF-I levels were measured in 124 PWS of which 103
(83.1 %) were treated with GH. IGF-I levels, adjusted for
age and gender, were higher in the GH-treated versus un-
treated patients with PWS (p\ 0.001). The AG and UAG
levels and AG/UAG ratio were not different between the
GH-treated and untreated patients with PWS (p = 0.423
for AG, p = 0.374 for UAG and p = 0.337 for AG/UAG
ratio).
After adjustment for age and gender, IGF-I was in-
versely associated with AG and UAG (p = 0.011 and
p = 0.008), but there was no significant association be-
tween IGF-I and the AG/UAG ratio (p = 0.993).
Table 2 Ghrelin levels of the three groups
PWS Controls Obese p between
groups*
PWS versus
controls*
PWS versus
obese*
Obese versus
controls*n = 138 n = 39 n = 50
Parameter Median (IQR) Median (IQR) Median (IQR)
AG (pg/ml) 129.1 (67.1–227.9) 82.4 (56.3–130.4) 40.3 (26.4–82.5) <0.001 0.016 <0.001 0.001
UAG (pg/ml) 135.3 (66.0–284.2) 157.3 (79.3–261.0) 35.8 (26.0–64.4) <0.001 0.868 <0.001 <0.001
AG/UAG ratio 1.00 (0.57–1.49) 0.61 (0.37–0.81) 1.16 (0.92–1.43) <0.001 0.001 0.069 <0.001
Bold values are statistically significant (p\ 0.05)
* p value between the groups
Endocrine (2015) 50:633–642 637
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Obese and controls
In healthy and obese controls, no significant differences in
ghrelin levels between boys and girls were found. Younger
age was associated with higher levels of AG and UAG
(p\ 0.001 and p = 0.001, resp), but the AG/UAG ratio
remained stable across age. BMI SDS was inversely cor-
related with AG and UAG levels (both p\ 0.001), but
positively with the AG/UAG ratio (p\ 0.001).
Discussion
Our study shows that AG levels are significantly higher in
PWS patients than in controls. In contrast to our expecta-
tions, UAG levels in PWS were similar to those in controls.
This resulted in a significantly higher AG/UAG ratio in
PWS than in controls. Remarkably, our study shows that
PWS patients in nutritional phase 2a, 2b, and 3, thus with
weight gain and/or hyperphagia, had a higher AG/UAG
ratio than those in nutritional phase 1a or 1b, without
weight gain or hyperphagia, whose AG/UAG ratios were
similar to age-matched controls.
In our large study group, we measured levels of acylated
and unacylated ghrelin separately using double-antibody
sandwich ELISAs specific for each isoform. This approach
prevents detection of inactive peptide fragments in the
samples. We also inhibited the deacylation of AG to UAG
by adding AEBSF to the blood samples [18, 19]. Many
previous studies used radioimmunoassays for total ghrelin
which detect both full-length, as well as inactive fragments,
of both ghrelin isoforms [4, 5, 20, 29–31], or samples were
not stabilized with an esterase inhibitor to prevent deacy-
lation of AG [32, 33]. As a result, our data cannot be
compared with those in earlier studies.
Both PWS and obese had a significantly higher AG/
UAG ratio than healthy controls. The reason for the higher
AG/UAG ratio in both groups was, however, completely
different. While PWS had higher AG levels with normal
UAG levels, obese controls had low AG levels with even
lower UAG levels. Based on the higher BMI in PWS pa-
tients, one would have expected lower AG and UAG levels
like in obese subjects. This might indicate that the abnor-
malities of the ghrelin system are specific for PWS. Only
two other studies reported AG or UAG levels in PWS and
compared them with obese controls, but neither study
added an inhibitor of AG degradation to the blood samples.
Both demonstrated significantly higher AG levels in PWS
than in obese controls [32, 33]. The ratio between AG and
UAG was not presented. Paik et al. did not report a sig-
nificant difference in UAG levels between PWS and obese
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Fig. 1 Ghrelin levels versus age for the three groups. These figures
show the of AG and UAG levels and the AG/UAG ratio of children
and young adults with PWS in black dots, of healthy controls in gray
triangles and of obese controls in gray crosses
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controls [33]. A possible explanation for these different
observations might be the method that was used to collect
the blood samples.
In contrast to our expectation, the median age of patients
with PWS in nutritional phase 1b was 3.5 years higher than
in phase 2a. Although hyperphagia is a constitutive marker
of PWS, we found in our large group that several older
patients were still in nutritional phase 1b, thus without
weight gain or hyperphagia. An explanation might be that
the patients in our group had an earlier diagnosis with earlier
attention for diet, physical exercise and GH treatment
starting at a young age [34], although it is not proven that this
approach can prevent hyperphagia. Parallel to the rise of the
nutritional phases, we found an increasing BMI, supporting
that the nutritional phases were correctly attributed.
Our results confirm our hypothesis that patients with
PWS without hyperphagia have a similar AG/UAG ratio as
age-matched controls, while patients with PWS with
weight gain and/or hyperphagia have an AG/UAG ratio
higher than that of age-matched controls. In nutritional
phase 2a, children with PWS gain weight without a change
in appetite or caloric intake. Phase 2b is associated with
weight gain and an increased interest in food, and phase 3
is characterized by hyperphagia, typically accompanied by
food-seeking and lack of satiety [3]. So in nutritional
phases 2a, 2b, and 3, the switch to the typical weight and
eating problems of PWS has already occurred. We found
that the AG/UAG ratio of children with PWS is already
increased in nutritional phase 2a, when there is only weight
gain but no hyperphagia. There is a considerable change in
the AG/UAG ratio between phase 1b and phase 2a and the
AG/UAG ratio remained at a similar high level in phases
Table 3 Age, BMI, and ghrelin levels per nutritional phase
Age (years) BMI (SDS) AG (pg/ml) UAG (pg/ml) AG/UAG ratio
n Median Range Median p* Median p* Median p* Median p*
PWS 138 9.9 0.2–29.4 1.0 <0.001 129.1 0.016 135.3 0.868 1.00 0.001
Nutritional phase 1a 13 0.5 0.2–4.1 -2.0 0.001 182.6 1.000 350.8 0.521 0.57 0.837
Nutritional phase 1b 37 8.9 0.6–22.3 -0.6 0.167 161.0 0.022 252.0 0.180 0.72 0.225
Nutritional phase 2a 12 5.3 1.5–9.3 0.9 <0.001 117.2 0.977 125.5 0.413 1.19 0.243
Nutritional phase 2b 44 11.2 2.2–29.4 1.6 <0.001 114.4 0.020 120.1 0.848 1.05 0.002
Nutritional phase 3 31 14.5 4.7–26.1 2.7 <0.001 99.2 0.217 73.1 0.165 1.26 0.005
Nutritional phase 4 1 14.6 3.2 56.1 596.8 0.09
Healthy controls 39 7.3 0.8–28.6 -0.2 82.4 157.3 0.61
Obese controls 50 9.8 4.3–16.9 2.8 <0.001 40.3 0.001 35.8 <0.001 1.16 <0.001
Bold values are statistically significant (p\ 0.05)
* Compared with age-matched healthy controls (HC). Phase: 1a PWS n = 13 versus HC n = 8 (median age 1.4 years, median BMI -0.1 SDS),
1b PWS n = 37 versus HC n = 26 (8.5 years, -0.1 SDS), 2a PWS n = 12 versus HC n = 12 (5.2 years, -0.9 SDS), 2b PWS n = 44 versus HC
n = 29 (9.0 years, 0.0 SDS), 3 PWS n = 31 verus HC n = 18 (13.9 years, 0.0 SDS)
Obese 
controls
Healthy
controls
PWS
3
PWS
2b
PWS
2a
PWS
1b
PWS
1a
A
G
/U
A
G
 r
at
io
3.0
2.0
1.0
0.0
p=0.009*
N   13       37           12                44   31       39             50
Age (yrs)# 0.5       8.9           5.3               11.2         14.5       7.3            9.8
                  (0.2-4.1)     (0.6-22.3)    (1.5-9.3)      (2.2-29.4)   (4.7-26.1)    (0.8-28.6)     (4.3-16.9)
BMI SDS§   -2.0       -0.6           0.9               1.6    2.7       -0.2            2.8
Deletion / mUPD^   7/6       14/18           4/6               27/14   17/11 
P-value of   0.837       0.225           0.243           0.002 0.005        _ <0.001
AG/UAG ratio
vs healthy controls◦ 
Nutritional phase
   _ _
Fig. 2 AG/UAG ratio of PWS per nutritional phase and of healthy
and obese controls. This boxplot shows the AG/UAG ratio of children
and young adults with PWS in the five nutritional phases and of
healthy controls and obese controls. The lower boundary is the 25th
percentile and the upper boundary the 75th percentile. The line in the
box represents the median. Lines are drawn from the smallest to the
largest observed value that is not an outlier. #Median (range) age in
years. §Median BMI SDS. ^Number of PWS patients with deletion
and mUPD. P value of AG/UAG ratio of the subjects in each
nutritional phase compared with age-matched healthy controls. *All
subjects in phase 1a and 1b combined and compared with all subjects
in phase 2a, 2b, and 3 combined
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2b and 3. Compared to age-matched controls, the AG/UAG
ratio in phase 2a, 2b, and 3 was higher, although not sig-
nificantly in phase 2a, probably due to the low number of
patients in phase 2a. This considerable change in AG/UAG
ratio between phase 1b and higher nutritional phases is in
line with the switch to weight gain followed by hyper-
phagia, which happens in the same period and supports the
hypothesis that ghrelin might be involved in this. Whether
this modification is the cause or the consequence of the
switch in the nutritional phases cannot be unraveled by our
study. Delhanty et al. suggested that UAG is a functional
inhibitor of AG which might suppress AG levels in humans
[16, 17]. Elaborating on this idea, the ratio between AG
and UAG levels (AG/UAG ratio) might be a more im-
portant parameter than individual AG and UAG levels. If
this hypothesis is correct, it could be that in patients with
PWS without weight gain and/or hyperphagia, in which the
AG/UAG ratio is normal, UAG levels are sufficiently high
to compensate for the elevated AG levels. However, the
UAG levels in patients with PWS from phase 2a onwards
are likely to be too low to modulate the effects of elevated
AG levels. The resulting higher AG/UAG ratio might in-
duce or contribute to the weight gain and hyperphagia. It is
unknown which factors determine UAG levels in healthy
subjects and PWS patients. Previous studies showed that
somatostatin (agonist) administration did not result in re-
duction of weight, food intake or appetite [35–37], but it
might be that AG and UAG levels are equally affected by
this treatment and that the AG/UAG ratio is not influenced.
UAG might be secreted via different mechanisms than AG
and rates of acylation and/or deacylation of AG might be
differently modulated. Also differences in clearance of
UAG relative to AG might play a role, but no reports are
available. Our findings provide a rationale for a role of
relatively decreased UAG levels in the abnormal eating
behavior in PWS. It would be interesting to investigate
whether a more physiological AG/UAG ratio could be
achieved by increasing the plasma UAG or decreasing the
plasma AG levels and/or bioactivity, and whether this
normalization of the AG/UAG ratio results in a reduction
of the hyperphagia.
AG and UAG levels and the AG/UAG ratio at various
ages in PWS show a wide variation. In the total group,
there was a distinct pattern with higher AG/UAG ratios in
the higher nutritional phases than in age-matched controls.
For individuals, this implies that a patient with PWS with a
higher AG/UAG ratio has a higher chance to be in a higher
nutritional phase.
As expected, PWS patients had a more favorable
metabolic profile with lower insulin levels and a lower
HOMA-IR than obese controls [7], while the IGF-I levels
were higher in the PWS than in the obese group. In PWS,
we found an inverse correlation between AG and UAG
levels and BMI and in addition also an inverse association
between UAG levels and HOMA-IR. This suggests that
low UAG levels in PWS are associated with less favorable
health aspects, such as a higher BMI and insulin resistance.
Previous studies have reported similar results in non-PWS
subjects, but no inhibitor was added to their blood samples
[38–40].
Our study showed no difference in AG/UAG ratios be-
tween GH-treated patients and untreated patients with
PWS, and there was also no significant association between
IGF-I levels and AG/UAG ratio. Thus, in our study, GH
treatment seems to have no effect on the AG/UAG ratio,
despite earlier notes of Hauffa and Petersenn in which GH-
treated was assigned as confounding factor in the natural
course of ghrelin concentrations [41]. We assume that this
study was not designed to investigate the effects of GH
treatment on ghrelin levels.
As blood sampling in children and young adults with
PWS is difficult and quite invasive, we collected only one
fasting sample. In our opinion, fasting samples are most
appropriate and we present the AG and UAG levels of a
large group of patients. It would be informative, however,
to conduct a longitudinal study in children with PWS, to
investigate whether the switch in eating behavior is closely
correlated with an increase in the AG/UAG ratio. In
Table 4 Comparison between non-obese PWS and healthy controls, and obese PWS and obese controls
Gender Age (years) BMI (SDS) AG (pg/ml) UAG (pg/ml) AG/UAG ratio
n m/f median median median median median
Non-obese PWS (BMI\ 2SDS) 100 43/57 8.9 0.4 140.1 150.7 0.89
Healthy controls 39 13/26 7.3 -0.2 82.4 157.3 0.61
Non-obese PWS vs healthy controls 139 NS NS NS 0.005 NS 0.003
Obese PWS (BMI[ 2SDS) 38 18/20 13.5 2.7 100.1 94.9 1.08
Obese controls 50 16/34 9.8 2.8 40.3 35.8 1.16
Obese PWS vs Obese controls 88 NS 0.013 NS <0.001 <0.001 NS
Bold values are statistically significant (p\ 0.05)
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addition, it would be of interest to determine whether PWS
patients show a postprandial decline in AG and UAG
levels.
Conclusion
We report that PWS patients have higher AG levels but
similar UAG levels compared to healthy controls, resulting
in a significantly higher AG/UAG ratio in PWS patients
than in controls. Obese controls have significantly lower
AG and UAG levels than PWS patients and healthy con-
trols, but also a high AG/UAG ratio. The reason for the
higher AG/UAG ratio in PWS and obese was, however,
completely different, as PWS had a high AG and obese a
very low UAG.
PWS patients without weight gain or hyperphagia had a
similar AG/UAG ratio as age-matched controls, in contrast
to those with weight gain and/or hyperphagia who had an
elevated AG/UAG ratio. The switch to excessive weight
gain in PWS seems to coincide with an increase in the AG/
UAG ratio, even prior to the start of hyperphagia.
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